These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

447 related items for PubMed ID: 19884364

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus.
    Jones ME.
    Clin Microbiol Infect; 2007 Jun; 13 Suppl 2():17-24. PubMed ID: 17488372
    [Abstract] [Full Text] [Related]

  • 3. Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin.
    Zhanel GG, Lam A, Schweizer F, Thomson K, Walkty A, Rubinstein E, Gin AS, Hoban DJ, Noreddin AM, Karlowsky JA.
    Am J Clin Dermatol; 2008 Jun; 9(4):245-54. PubMed ID: 18572975
    [Abstract] [Full Text] [Related]

  • 4. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
    Zhanel GG, Voth D, Nichol K, Karlowsky JA, Noreddin AM, Hoban DJ.
    J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
    [Abstract] [Full Text] [Related]

  • 5. In vivo antibacterial activity of S-3578, a new broad-spectrum cephalosporin: methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa experimental infection models.
    Tsuji M, Takema M, Miwa H, Shimada J, Kuwahara S.
    Antimicrob Agents Chemother; 2003 Aug; 47(8):2507-12. PubMed ID: 12878512
    [Abstract] [Full Text] [Related]

  • 6. Ceftobiprole: a novel cephalosporin with activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA).
    Barbour A, Schmidt S, Rand KH, Derendorf H.
    Int J Antimicrob Agents; 2009 Jul; 34(1):1-7. PubMed ID: 19261449
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European origin.
    Pillar CM, Aranza MK, Shah D, Sahm DF.
    J Antimicrob Chemother; 2008 Mar; 61(3):595-602. PubMed ID: 18218646
    [Abstract] [Full Text] [Related]

  • 9. Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus strains with reduced susceptibility to daptomycin, linezolid or vancomycin, and strains with defined SCCmec types.
    Farrell DJ, Flamm RK, Sader HS, Jones RN.
    Int J Antimicrob Agents; 2014 Apr; 43(4):323-7. PubMed ID: 24411474
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Ceftobiprole: an extended-spectrum anti-methicillin-resistant Staphylococcus aureus cephalosporin.
    Anderson SD, Gums JG.
    Ann Pharmacother; 2008 Jun; 42(6):806-16. PubMed ID: 18477729
    [Abstract] [Full Text] [Related]

  • 13. [Analysis of the pathogenic characteristics of 162 severely burned patients with bloodstream infection].
    Gong YL, Yang ZC, Yin SP, Liu MX, Zhang C, Luo XQ, Peng YZ.
    Zhonghua Shao Shang Za Zhi; 2016 Sep 20; 32(9):529-35. PubMed ID: 27647068
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006).
    Fritsche TR, Sader HS, Jones RN.
    Diagn Microbiol Infect Dis; 2008 May 20; 61(1):86-95. PubMed ID: 18385000
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Intensive therapy with ceftobiprole medocaril of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
    Vaudaux P, Gjinovci A, Bento M, Li D, Schrenzel J, Lew DP.
    Antimicrob Agents Chemother; 2005 Sep 20; 49(9):3789-93. PubMed ID: 16127054
    [Abstract] [Full Text] [Related]

  • 19. Clinical profile of ceftobiprole, a novel beta-lactam antibiotic.
    Noel GJ.
    Clin Microbiol Infect; 2007 Jun 20; 13 Suppl 2():25-9. PubMed ID: 17488373
    [Abstract] [Full Text] [Related]

  • 20. Ceftobiprole medocaril is an effective treatment against methicillin-resistant Staphylococcus aureus (MRSA) mediastinitis in a rat model.
    Barnea Y, Navon-Venezia S, Kuzmenko B, Artzi N, Carmeli Y.
    Eur J Clin Microbiol Infect Dis; 2014 Mar 20; 33(3):325-9. PubMed ID: 24030718
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.